Vir Biotechnology (VIR) Total Liabilities (2018 - 2026)
Vir Biotechnology (VIR) posted Total Liabilities of $212.8 million for Q1 2026, down 10.41% sequentially from $237.5 million in Q4 2025, and down 19.36% YoY from $263.9 million in Q1 2025.
Vir Biotechnology (VIR) Total Liabilities (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Total Liabilities for 9 years, with the latest figure at $212.8 million in Q1 2026.
- Quarterly Total Liabilities fell 19.36% year-over-year to $212.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $212.8 million (down 19.36% YoY) and the FY2025 annual result came in at $237.5 million, down 4.38% from the prior year.
- Total Liabilities retreated to $212.8 million in Q1 2026 per VIR's latest filing, from $237.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $886.1 million in Q1 2022 and troughed at $212.8 million in Q1 2026.
- A 5-year average of $401.3 million and a median of $263.9 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 108.27% in 2022, then plunged 64.52% in 2024.
- Over 5 years, Total Liabilities stood at $724.1 million in 2022, then slumped by 54.59% to $328.8 million in 2023, then slipped by 24.45% to $248.4 million in 2024, then declined by 4.38% to $237.5 million in 2025, then dropped by 10.41% to $212.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $212.8 million, $237.5 million, and $223.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 232.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 232.31 Mn |
| Mar 31, 2026 | 212.82 Mn |
| Dec 31, 2025 | 237.55 Mn |
| Sep 30, 2025 | 223.36 Mn |
| Jun 30, 2025 | 245.06 Mn |
| Mar 31, 2025 | 263.91 Mn |
| Dec 31, 2024 | 248.43 Mn |
| Sep 30, 2024 | 257.63 Mn |
| Jun 30, 2024 | 235.89 Mn |
| Mar 31, 2024 | 246.61 Mn |
| Dec 31, 2023 | 328.82 Mn |
| Sep 30, 2023 | 369.81 Mn |
| Jun 30, 2023 | 433.67 Mn |
| Mar 31, 2023 | 695.14 Mn |
| Dec 31, 2022 | 724.13 Mn |
| Sep 30, 2022 | 546.12 Mn |
| Jun 30, 2022 | 666.98 Mn |
| Mar 31, 2022 | 886.12 Mn |
| Dec 31, 2021 | 522.42 Mn |
| Sep 30, 2021 | 333.94 Mn |